Main Outcome Measure(s):
Serum AMH levels were measured by a conventional AMH ELISA (EIA AMH/MIS) and a hypersensitive ELISA (PicoAMH, AnshLabs) on the same sample.

Result(s):
Using a conventional assay, serum AMH was detectable (≥3 pmol/L) in 6.7% and in 10.7% of the samples corresponding to amenorrheic or cycling patients, respectively (nonsignificant). By contrast, with PicoAMH, serum AMH was detectable (≥0.07 pmol/L) in 71.4% of the samples from cycling women vs. 16.7% of the samples from amenorrheic patients. Multivariate regression analysis showed that among putative contributors, only the menstrual status (r = 0.307) and serum FSH level (r = −0.546) were independently correlated to a detectable serum AMH with the picoAMH assay exclusively.

Conclusion(s):
The picoAMH assay, allowing measurement of very low AMH concentrations in human serum, should refine postchemotherapy ovarian follow-up in young women.

New Discussion Features!

NEW! Open access free discussion forums on EVERY article in Fertility and Sterility! Just go to the issue and click on article title. You will be able to submit comments questions or share your thoughts on the paper-- Speak your mind!